Lipocine Announces Distribution And License Agreement With SPC Korea To Commercialize TLANDO In South Korea
Portfolio Pulse from Benzinga Newsdesk
Lipocine Inc. has entered into a distribution and license agreement with SPC Korea to commercialize TLANDO in South Korea. Lipocine will receive upfront, regulatory, and sales milestone payments, as well as royalties on net sales.
October 31, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lipocine Inc. has signed a significant agreement with SPC Korea to market TLANDO in South Korea, which includes upfront payments, milestone payments, and royalties.
The agreement with SPC Korea is a positive development for Lipocine as it opens a new market for TLANDO, potentially increasing revenue through upfront payments, milestone payments, and royalties. This partnership is likely to boost investor confidence and positively impact LPCN's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90